REFERENCES

1) Kumar V, Abbas A K,Fausto N (2004),*Robbins and Cotran* : *Pathalogic Basis of Diseases*. Saundres Elsevier Inc.7th edn. 521.
2) Peter A. Mayes (1988),*Lipids of Physiological Significance. Harper's Biochemistry*. Appleton & Lange.21st edn.130.
3) Joan F. Zilva &.P.R Pannal (1985),*Clinical Chemistry in Diagnosis and Treatment.* Lloyd-Luke Medical Books Ltd. 4TH edn.232-241.
4) Katheleen M. Botham& Peter A.Mayes (2006)*, Lipid Transport & Storage. Harpers Illustrated Biochemistry* .McGraw Hill. 27th edn. 217.
5) Cyril A. Keele, Eric Neil, and Norman Joels (2004),*Samson Wrights Applied Physiology*. Oxford University Press.13th edn.508-511.
6) Dr. A. C. Deb (2006*), Fundamentals of Biochemistry*. New Central Book Agency. 8th edn. 270.
7) Philip D. Mayne (1996),*Clinical Chemistry in Diagnosis and Treatment*. Baron, Whicher and Lee. 6th edn. 206.
8) David A. Bender, & Peter A. Mayes, (2006).*Gluconeogenisis& the Control of BloodGlucose,Harpers illustrated Biochemistry*.McGraw Hill. 27th edn.175.
9) Babulayeb Mukhopadhyay; Naveed Satta; Milesr Fisher: (2005).*Diabetes and Cardiac Diseasein South Asians*. British Journal of Diabetes and Vascular Disease. 5(5):253-259.
10) Dr. A. C. Deb. (2006).*Fundamentals of Biochemistry*. New Central Book Agency .8th edn. 527.
11) Peter A. Mayes (1988)*, Cholesterol Synthesis, Transport, Excretion*. *Harper's Biochemistry*. Appleton & Lange. 21st edn. 241.

12) Peter A. Mayes (1988), *Lipid Transport & Storage*.*Harper's Biochemistry.*Appleton & Lange. 21st edn. 226.

13) Reddy K.S. (1993), *Cardiovascular Diseases in India*. World Health Stat. Q. 46, 101-107.

14) Geethanjali, F.S., Jose, V.J. and Kanagasabapathy (2002*), Lipoprotein (a) phenotypes in South Indian patients with coronary artery diseases*.Indian Heart J. 54,50-53.

15) Mohan. V., Deepa, R., Harnath, S.P. Premalatha. G., Rema. M., Sastry. N.G. and Enas,E.A. (1998),*Lipoprotein (a) is an independent risk factor for Coronoryarterydisease in NIDDM patients in South Indian*. Diab.Care. 2,1819-1823.

16) Danesh J, Collins R, Peto R (2000),*"Lipoprotein (a) and Coronary Heart Disease Meta-analysis of Prospective Studies*" Circulation 102(10).

17) Smolders B, Lemmens R, Thijs V (2007*),"Lipoprotiein (a) and stroke: a Meta Analysis Of Observational Studies*" Stroke 38 (6):1959-66.

18)Schreiner PJ, Mosrisett JD, Sharrett A R , Patsh W, Tyroler AA, Wu K, Heiss.(1993), G *"Lipoprotein (a) as a risk factor for clinical athersclerosis*"Arterioscler.Thromb. 13(6)826-33.

19)Berg. K. (1963*),A new serum type system in man* "The Lp system" ActaPathol Microbiol.Scand 59:369-82.

20)Mc Lean JW, Tomlinson JE, Kuang WJ , Eaton DL, Chen EY Fless GM, Scanu AM, Lawn RM (1987),*"c DNA sequence of human apolipoprotein (a) is homologous to plasminogen".*Nature. 330 (6144): 132-7.

21) Robbins and Cotran(2004),*Pathalogic Basis of Diseases*, Saunders, 7th edn. 520-522.

22)Wilde C. (2003),*Hidden causes of heart attack and stroke: Inflammation,* Cardiology's New Frontier.AbigonPress.182-183.

23) Caplice N M. Panntta C, Peterson T E, Kleppe LS, Mueske C S, Kostner G M, Bronze G J,Simari RD (2001), "*Lipoprotein (a) binds and inactivates tissues factor pathway inhibitor; a novel link between lipoprotein(a) and thrombosis*" Blood 98(10):2980-7.

24) Singla S, Kaur K, Kaur G, Kaur H, Kaur J, Jaswal S.(2009), *Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic contro*l.Int J Diabetes Dev Ctries.Apr;29(2):80-4

25) D. Rajasekar ,K.S.S.Saibabaetal. (2004). *Lipoprotein (A): BetterAssesor of CoronoryHeart Disease Rglucemiccontrolisk in South Indian Population*.Indian Journal of Clinical Biochemistry,19(2) 53-59.

26) Lisa Nainggolan(2009). *New Data Show That Lp(a).Is a casual Factor For MI, Researchers say*. Journal of the American Medical Association.

27) BorgeG.Nordestgaard et al. (2010)*Lipoprotein (a) as a Cardiovascular Risk Factor :CurrentStatus.*Eur Heart J.;31(23):2844-2853.

28) James Pendleton (2009*) Lipoprotein (a) and cardiovascular Disease:Role in Human*

*Physiology and Pathology.*1.

29) Conigrave K M, Saunders JB. Rezink RB, et al (1993), Prediction of alcohol–related harm by laboratory test results. Clin Chem.; 39:2266-2270.

30) Whitfield J B. (2001).*Gamma glutamyl transferase*. Crit Rev Clin Lab Sci. Aug; 38(4):263-355.

31) Lppi G, Tagher G, Montaganna M.,Salvago G L, Guidi GC.,(2007).*Relationship between gamma-glutamyl transferase, lipids and lipoprotein (a) in the general population,* Clin Chem Acta:384(1-2):163-6.

32)Turget O, Yilmaz A, Yalta K, Karadas F, BirhanYilmaz M,(2006).*gamma glutamyl transferase is a promising biomarker for cardiovascular risk*. Med Hypothesis ; 67(5):1060-4.

33) Turgut O, Tandogan I, Gurlek A. (2009), *Association of gamma-glutamyl transferasewith Cardiovascular risk: a prognostic outlook*. Arch Med Res May;40 (4):318-20.

34) Mason, J.E., Starke, R.D. and Van Kirk, J.E. (2010), *Gamma-Glutamyl Transferase : A Novel Cardiovascular Risk Biomarker*. Preventive Cardiology, 13:36-41.

35) Pompella A, Emdin M, PassinoC, Paolicchi A.(2004); *The Significance of serum gamma-Glutamyltransferase in cardiovascular diseases*.Clin Chem Lab Med.;42(10):1085-95.